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Abstract
Background: Intermittent preventive treatment during pregnancy (IPTp) at routine antenatal care (ANC) clinics is
an important and efficacious intervention to reduce adverse health outcomes of malaria infections during
pregnancy. However, coverage for the recommended two IPTp doses is still far below the 80% target in Tanzania.
This paper investigates the combined impact of pregnant women’s timing of ANC attendance, health workers’ IPTp
delivery and different delivery schedules of national IPTp guidelines on IPTp coverage.
Methods: Data on pregnant women’s ANC attendance and health workers’ IPTp delivery were collected from ANC
card records during structured exit interviews with ANC attendees and through semi-structured interviews with
health workers in south-eastern Tanzania. Women’s timing of ANC visits and health worker’s timing of IPTp delivery
were analyzed in relation to the different national IPTp schedules and the outcome on IPTp coverage was modelled.
Results: Among all women eligible for IPTp, 79% received a first dose of IPTp and 27% were given a second dose.
Although pregnant women initiated ANC attendance late, their timing was in line with the national guidelines
recommending IPTp delivery between 20-24 weeks and 28-32 weeks of gestation. Only 15% of the women
delayed to the extent of being too late to be eligible for a first dose of IPTp. Less than 1% of women started ANC
attendance after 32 weeks of gestation. During the second IPTp delivery period health workers delivered IPTp to
significantly less women than during the first one (55% vs. 73%) contributing to low second dose coverage.
Simplified IPTp guidelines for front-line health workers as recommended by WHO could lead to a 20 percentage
point increase in IPTp coverage.
Conclusions: This study suggests that facility and policy factors are greater barriers to IPTp coverage than women’s
timing of ANC attendance. To maximize the benefit of the IPTp intervention, revision of existing guidelines is
needed. Training on simplified IPTp messages should be consolidated as part of the extended antenatal care
training to change health workers’ delivery practices and increase IPTp coverage. Pregnant women’s knowledge
about IPTp and the risks of malaria during pregnancy should be enhanced as well as their ability and power to
demand IPTp and other ANC services.
Background
Malaria is still a major cause of morbidity and mortality
in Tanzania, especially for small children and pregnant
women [1]. About 1.7 million pregnant women contract
malaria each year in Tanzania [2] leading to a high risk
of suffering from severe anaemia, spontaneous abortion,
preterm delivery, congenital infection, still birth and
low-birth weight [3,4]. Malaria during pregnancy is a
contributing factor to both maternal death [5] and
infant morbidity and mortality [6,7]. Infection rates have
been found to be especially high in women in their first
and second pregnancy [4,8], but also depend on other
factors such as endemicity, immunity, age, trimester and
co-morbidities [9].
Committing themselves to the Abuja targets, Tanzania
and other countries in sub-Saharan Africa adopted the
World Health Organization’s (WHO) recommendation
for malaria prevention and control during pregnancy
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[10,11]. In areas of stable malaria transmission in sub-
Saharan Africa, this means the implementation of an
intervention package into the antenatal care (ANC) ser-
vices including the use of insecticide-treated nets (ITN)
and intermittent preventive treatment in pregnancy
(IPTp) as well as effective case management of malaria
and anaemia [12]. Thus, every Tanzanian pregnant
woman attending an ANC clinic is entitled to receive a
national voucher for a subsidized ITN, known as Hati
Punguzo ("discount card” in Swahili) and IPTp [13]. In
2003, WHO defined IPTp as the delivery of two doses
of an anti-malarial to pregnant women at the beginning
of the second and third trimester irrespective of the pre-
sence of signs for a malaria infection [14]. Sulphadox-
ine-pyrimethamine (SP) is the drug currently used for
IPTp in areas of Africa where malaria is transmitted by
Plasmodium falciparum as it has been shown to be a
cheap, safe and effective single-dose treatment
[12,15,16]. There is also evidence that the intervention
is well accepted by women in various African settings
[17,18]. Taking health workers’ difficulties to assess
gestational age into account, WHO modified and simpli-
fied the IPTp recommendations in 2004: “beginning of
the second trimester” was replaced by “after quickening”
(first noted movements of the foetus) and “third trime-
ster” by “at least one month apart”. This change in
wording also implies that more than two doses can be
administered [12,19]. In the context of the HIV epi-
demic and increasing SP resistance, discussions have
arisen on the optimal number of IPTp doses required to
maintain protection for the mother and her child. Based
on its relatively low HIV prevalence rate of 6% [20],
Tanzania is the only East-African country to keep a two
dose regimen regardless of HIV status [21] as WHO
recommends the introduction of a three dose regimen
where HIV prevalence is above 10% [12].
In Tanzania, two different IPTp recommendations are
available and they partially disagree with current WHO
recommendations (see Figure 1). Firstly, the revised
national malaria diagnosis and treatment guidelines
from 2005 recommend the administration of a first dose
of IPTp between 20-24 weeks and a second dose
between 28-32 weeks of gestation [22]. This recommen-
dation is critically different from the current WHO
recommendation that all pregnant women in areas of
stable malaria transmission should receive at least two
doses of IPTp after quickening and at least one month
apart [12]. Secondly, based on WHO’s new ANC model
and drawing on the experiences from Kenya, Tanzania
developed in 2002 the Focused Antenatal Care (FANC)
guidelines with specific reference to malaria in preg-
nancy [23]. The FANC guidelines in principle follow the
revised WHO IPTp recommendation by stating that
IPTp “can be given at any point in pregnancy after 16
weeks as long as [the doses are] one month apart” [23:
81] and “is safe from quickening up to 40 weeks of
gestation” [23: 86]. Confusingly, the guidelines also still
recommend IPTp to be delivered between 20-24 weeks
and again between 28-32 weeks of gestation [23: 104].
Tanzania was among the first countries to adopt IPTp
as a national strategy in 2000 along with Malawi, Kenya,
Uganda and Zambia [24]. ANC attendance is high with
62% of women attending at least four times [1]. Yet cov-
erage is still far from reaching the target of 80% IPTp
coverage by 2010 as proposed by the Roll Back Malaria
Partnership and set in Tanzania for 2012 [11,25]. Cover-
age levels of the second IPTp dose are particularly low.
According to the Tanzanian Malaria and HIV Indicator
Survey 2007/08 57% of all pregnant women reported
receiving one dose of IPTp but only 30% said they were
given a second dose during an ANC visit [20]. Disap-
pointing second dose coverage results of below 40%
have also been found by other studies from Tanzania
and East Africa [26-30].
Recent studies have stressed the need to investigate
the impact of available guidelines on implementation,
health worker practices and drug stock-outs at the
health facilities in order to understand the reasons for
low IPTp coverage [26-28,30,31]. However, only a few
studies have addressed these factors so far. Instead, stu-
dies have associated low IPTp uptake with women’s late
initiation and irregular attendance of ANC services
[29,32,33]. Others have investigated the relationship
between IPTp uptake and women’s knowledge about
malaria [28,32-35]. Yet others have explored the influ-
ence of pregnant women’s age, marital status, educa-
tional level, socio-economic status or parity on IPTp
uptake [26,35,36]. Overall, studies with a focus on
women’s individual characteristics were not able to
explain low IPTp levels [27-29,35,36]. Two recent stu-
dies from Tanzania demonstrated that delivery of IPTp
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Figure 1 The two national IPTp guidelines
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was influenced by facility and policy level factors.
Marchant et al. [30] analysed national household and
facility survey data from Tanzania and identified insuffi-
cient SP stocks at the health facilities and restrictive
guidelines as the main reasons for low IPTp delivery.
Similarly, Anders et al. [26] argued that revised guide-
lines and improved drug stocks would allow for delivery
of IPTp at an earlier gestational age and to increase
IPTp coverage.
The aim of this paper is to assess the combined
impact of women’s timing of ANC attendance, health
workers’ IPTp delivery and different delivery schedules
of national IPTp guidelines on IPTp coverage. The
study used ANC card records collected during exit
interviews with ANC attendees to analyze pregnant
women’s timing of ANC visits and health workers’ deliv-
ery and timing of IPTp in relation to the main IPTp
guidelines in use in Tanzania and to model the antici-
pated outcome of a second set of guidelines on IPTp
coverage.
Methods
Study area
This study on IPTp coverage was conducted in the
frame of a wider research project that explored determi-
nants of access to ANC and IPTp services in the Kilo-
mbero and Ulanga Districts of the Morogoro Region in
south-eastern Tanzania between April 2007 and May
2009. The two districts are divided by the floodplain of
the Kilombero River which is delimited by the
Udzungwa Mountains to the north and by the Mahenge
Mountains to the south. Large parts of the valley are
regularly flooded during the rainy season from Novem-
ber to May.
The study area coincides with a Demographic Surveil-
lance System (DSS) that encompasses a total of 25 vil-
lages of the two districts with an estimated total
population of 92’000 in 2008 [37,38]. In the early 1990s,
malaria transmission in this area was amongst highest in
Tanzania with a mean entomological inoculation rate
(EIR) of over 300 infective bites per person per year
[39]. Although malaria transmission in the area has
been reduced substantially through the use of untreated
and insecticide-treated nets and effective malaria drugs,
it remains high and perennial [40,41]. Malaria is still the
most commonly diagnosed cause of illness in health
facilities [42], but there is recent evidence that malaria
is over-diagnosed, especially in the urban and peri-
urban areas (personal communication V. D’Acremont).
The area is predominantly rural and households rely
heavily on agriculture of rice, maize, banana and cas-
sava. During the rice planting and harvesting seasons
many people move for several months to temporary
shelters in distant farming sites [43].
The Tanzanian public health system consists of a wide
network of dispensaries, health centres and hospitals
with each facility serving between 3,300 and 7,000 peo-
ple [44]. At the time of study a total of 13 first and sec-
ond-level health facilities offered regular out-patient
services within the DSS area. Out of these, 12 (ten gov-
ernment and two faith based) facilities provided ANC
services for pregnant women on a weekly or daily basis
from Monday to Friday. Two district hospitals provide
referral care for complicated cases. In the course of the
Tanzanian Health Sector Reform the districts have
introduced a cost-sharing scheme in public facilities,
including an exemption policy for pregnant women and
children under five years of age.
DSS records suggest that in 2008, 3,033 women
became pregnant in the Kilombero and Ulanga DSS.
Women reported an average of 3.1 visits to ANC clinics
over the course of a pregnancy (personal communica-
tion: M. Alexander). Data collected from the Health
Management Information System (HMIS) on the DSS
area indicated that IPTp coverage had increased from
24% to 45% between 2006 and 2008 for one IPTp dose
and from 7% to 21% for two doses (Gross, unpublished
data).
Study design and study population
The study draws on data from two study components of
the larger research project: 1) in-depth interviews with
health workers at the ANC clinics were conducted in
June 2007 and 2) exit interviews with ANC attendees
were performed over a five month period between June
and October 2008.
In-depth interviews with 18 health workers at 12 ANC
clinics were conducted, including all health workers rou-
tinely working at the ANC clinic and available on the
day of visit. Between one to three health workers were
interviewed per health facility.
A total of 440 pregnant women visiting an ANC
clinic participated in the exit interviews. Ten facilities
(nine government facilities and one faith based facility,
five in the Kilombero district and five in the Ulanga
district) were selected and visited once per month for
one day. Since accessibility of health services in this
rural context is constrained through seasonal condi-
tions such as weather, agricultural work or availability
of money, the exit interviews were scattered over sev-
eral months. Two other health facilities in the study
area (one government facility and one faith based facil-
ity) were not included in the study because very few
pregnant women attended ANC services there. On
average, 12 randomly selected pregnant women were
interviewed per visit (min-max = 1-21) adding up to a
total of 43 pregnant women interviewed per health
facility (min-max = 28-79).
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Data collection instruments
Health worker in-depth interviews
The interviews explored a) health workers’ knowledge
and attitudes towards the IPTp strategy, and b) their
perception on factors influencing IPTp delivery. A semi-
structured interview guide was designed in English and
piloted outside the study area. The interview guide
ensured the coverage of the main topics, but intervie-
wees were encouraged to express their opinions and
concerns freely. The interviews were translated and
administered in Swahili. All but one of the interviews
were tape-recorded after obtaining written informed
consent from the health workers.
Exit interviews with ANC attendees
Participants were interviewed by two trained local
female field workers after obtaining the women’s
informed consent. The main investigator supervised
data collection during the two first rounds and checked
the completeness of the data collected.
Information was collected using a structured question-
naire. The questionnaire was designed in English, trans-
lated to Swahili, back-translated and pre-tested outside
the study area. Since the exit interviews were conducted
in the frame of a larger research project to investigate
pregnant women’s access to ANC and IPTp services,
questions were related to a) demographic characteristics,
b) knowledge about ANC services and motivation to
attend the ANC clinics, and c) ANC service utilization,
but also inquired d) women’s knowledge on malaria pre-
vention, and e) their IPTp use. Additionally, data on the
number and timing of ANC visits and IPTp doses
received were copied from the ANC cards in order to
avoid recall bias.
Data analysis
The in-depth interviews with the health workers were
transcribed and translated into English. Analysis was
done using the qualitative data management software
MaxQDA2 (Lucanus GmbH, Berlin, Germany). Text
segments were coded into categories using qualitative
content analysis [45]. Key themes emerging around
health workers’ knowledge on and experiences with the
IPTp strategy were cross-tabulated in order to explore
differences between and within health facilities.
From the exit interviews mainly ANC card data were
analysed for the purpose of this study. Demographic
data on marital status, socio-demographic status and
level of education will not be investigated in this paper
as several previous studies from Tanzania and elsewhere
have not demonstrated any association between these
characteristics and IPTp uptake [1,27,30,35].
Data were double-entered using Microsoft Access,
validated with EpiInfo version 3.3.2 (EpiInfo Association,
Denmark) and analysed in Stata 10 (StataCorop, College
Station, Texas, USA). Descriptive results are presented
using medians and interquartile ranges (IQR = 75th-25th
percentile). Differences in proportions were calculated
using chi-square-test and Fisher’s exact test where
appropriate. For all statistical tests a two-sided P-value
less than 0.05 was considered significant.
Firstly, women’s timing of ANC visits and their elig-
ibility for IPTp according to national guidelines were
assessed. Women were assumed to be eligible for IPTp
doses if they attended the ANC clinic between 20-24
weeks and/or 28-32 weeks of gestation. Secondly, health
workers’ IPTp delivery and its timing were evaluated in
relation to the national guidelines by using ANC card
records on women’s gestational age at the time of IPTp
receipt. In order to avoid biases resulting from the
inclusion of women who according to guidelines were
not yet eligible for IPTp due to their low gestational
age, IPTp uptake was analysed for two sub-samples: 1)
women of at least 20 weeks of gestation and 2) women
of at least 28 weeks of gestation. Thirdly, it was esti-
mated how the two different schedules of the national
IPTp policies available in the malaria diagnosis and
treatment guidelines and the FANC guidelines fit with
women’s timing of ANC attendance and health workers’
IPTp delivery and timing. For simplicity, the two IPTp
guidelines will be denoted as restrictive IPTp guidelines
(recommending IPTp administration between 20-24 and
28-32 weeks of gestation) and simplified IPTp guidelines
(recommending two doses of IPTp after quickening and
at least one month apart) (Figure 1). For the simplified
IPTp guideline, correct IPTp delivery was defined as
two doses administered at any time between 20 weeks
of gestation, which is the time when most women have
already recognized first movements of the foetus [46],
and 40 weeks of gestation as long as they are one
month apart. Finally, the combined impact of women’s
timing of ANC attendance and health worker’s delivery
and timing of IPTp on the effectiveness of the IPTp
strategy was assessed for each of the two national IPTp
guidelines. Only women who had made at least two
ANC visits were included (N = 189) in the sample.
Effectiveness loss was calculated in steps by calculating:
1) the number of women who attended ANC services
twice timely according to the guidelines in order to be
eligible for IPTp doses; and 2) the number of women
who attended timely and received one or two doses of
IPTp.
Ethical considerations
The study was carried out in the frame of the ACCESS
Programme which has been cleared by the National
Institution for Medical Research of Tanzania (NIMR/
HQ/R.8c/Vol. I/66) [47]. The study was also approved
by the review boards of the Swiss Tropical and Public
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Health Institute (STPH), formerly known as Swiss Tro-
pical Institute (STI), and the Ifakara Health Institute
(IHI), formerly known as Ifakara Health Research and
Development Centre (IHRDC). The study was discussed
and approved by the district coordinators for Reproduc-
tive-and-Child-Health (RCH) and staff in-charge was
asked for permission to conduct the study at their facil-
ities. Oral or written consent was obtained from all
pregnant women and health-workers participating in the
study after explaining the purpose of the study to them
and informing them of their right to withdraw at any
time. Health workers were asked for the permission to
tape-record the interviews.
Results
Study population
A total of 18 health workers participated in in-depth
interviews. They had between 0.5 and 24 years of work-
ing experience at the specific health facility and obtained
different professional qualifications: 44% (8/18) were
medical attendants (attended a one-year training), 22%
(4/18) were MCH (Mother and Child Health) Aides
(attended a two-year training), 22% (4/18) were certifi-
cated Nurse Midwifes (attended a four-year nursing
training or upgrade training) and 6% (1/18) were Nur-
sing Officers (attended a six-year training in nursing).
Of the 440 pregnant women who participated in the
exit interviews, 10 women were excluded from the ana-
lysis because their ANC cards did not contain informa-
tion on gestational age. Table 1 summarizes the
characteristics of the 430 participants. The median age
of the respondents was 25 years (IQR = 31-21) and 15%
(62/430) of all women were 19 years old or younger.
Among all women, 52% (225/430) had completed 7
years of primary school, 88% (377/430) were married
and 20% (84/430) were in their first pregnancy. Overall,
the median number of pregnancies was 3 (IQR = 5-2,
including the current pregnancy). On the day of the
interview, the majority of women were either between
20-24 weeks (43%, 185/430) or between 28-32 weeks of
gestation (30%, 128/430). Median gestational age at the
time of the interview was 24 weeks (IQR = 28-20).
Among all participants, 56% (241/430) attended the
ANC clinic for the first time in their current pregnancy
on the day of the interview. The median number of
ANC visits was one (IQR = 2-1).
Knowledge about IPTp among health workers
Health workers’ awareness about the IPTp strategy was
high, but concentrated on the restrictive IPTp schedule.
The majority of interviewees (11/18) explained in line
with the restrictive IPTp guidelines, that IPTp should be
administered between 20-24 weeks and 28-32 weeks of
gestation, or in the fifth and seventh months. However,
some health workers were confused as to when and how
many doses of IPTp to administer. A third of the health
workers (7/18) reported a deviant IPTp schedule: two
health workers who were working in the same health
facility indicated that they start giving the first SP dose
after 16 weeks of gestation; another three health workers
coming from two health facilities said they would give a
total of three doses of SP, but were confused as to when
to deliver them; three other health workers from differ-
ent facilities reported giving SP up to the 34th and 36th
week respectively. All seven health workers who
reported deviant IPTp schedules stated that they had
been instructed in a seminar to extend the schedule or
increase the number of doses.
Knowledge and attitudes about malaria prevention
among pregnant women
Awareness about IPTp was not high among the preg-
nant women interviewed. 34% (148/430) of the pregnant
women mentioned IPTp spontaneously as a service that
Table 1 Socio-demographic characteristics of the
respondents
Characteristic % (n)
N = 430
Age groups
<20 15 (62)
20-24 33 (132)
25-29 20 (83)
30-34 18 (72)
35-39 11 (44)
>39 3 (12)
Education level*
No education 24 (103)
Incomplete primary 23 (99)
Primary + 52 (225)
Marital status
Married or living with partner 88 (377)
Single or separated 12 (50)
Parity
Para 1 19 (84)
Para 2-4 54 (231)
Para 5+ 27 (115)
Gestational age at day of interview
<20 weeks 14 (60)
20-24 weeks 43 (185)
25-27 weeks 3 (14)
28-32 weeks 30 (128)
>32 weeks 10 (43)
No. of women attending the first time 56 (241)
No. of women attending the second time 27 (117)
No. of women attending the third or more time 17 (72)
*does not add up to 100% due to missing values.
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they should receive at the ANC clinics. Asking the parti-
cipants specifically about means of malaria prevention
that they expect to get at the ANC clinic, SP/Fansidar/
antimalarial was stated by 64% (277/430). 17% (75/430)
did not know. Most women were aware that they get
malaria prevention for their own (13%, 56/430) or for
the child’s protection (27%, 118/430) or for both mother
and child (36%, 155/430). However, almost a quarter of
the participants (23%, 99/430) answered the question
“why do they provide you with malaria prevention when
you go to the ANC clinic” with “I don’t know”.
Pregnant women’s timing of ANC visits
Pregnant women’s ANC attendance was in line with the
restrictive IPTp schedule as most of them attended at
20-24 and 28-32 weeks of gestation. Figure 2 presents
pregnant women’s gestational age at their first, second,
third and fourth ANC visit. It illustrates that the major-
ity of women (57%, 247/430) were already between 20-
24 gestational weeks at their first visit. Median gesta-
tional age at the first visit was 20 weeks which is consis-
tent with the national average of 20.1 gestational weeks
among health facility users [48]. Around half of the
women were between 28-32 weeks of gestation at their
second, third or fourth visit.
The majority of pregnant women attended at least
once during a time period in which they were eligible
for a first and/or a second IPTp dose at their ANC visits
(Figure 3). The number of visits made during the two
IPTp delivery periods specified by the restrictive guide-
lines was analysed for the two sub-samples of women of
at least 20 and 28 weeks of gestation. 81% (299/370) of
the women at 20 and more weeks of gestation attended
the ANC clinic in a way that they were at least once eli-
gible for a first dose of IPTp between 20-24 weeks. 15%
(55/370) were not eligible for IPTp because they delayed
ANC attendance until after 24 weeks of gestation.
Among the women who were at least 28 weeks of gesta-
tion 92% (157/171) were eligible at one or more ANC
visits for an IPTp dose between 28-32 weeks of gesta-
tion. The fact that only 8% of the women did not attend
between the 28-32 weeks of gestation indicates that vis-
its were more timely during the second delivery period
compared to the first delivery period. Analysis for all
women who had reached 28 weeks of gestation showed
that 60% (102/171) attended both between 20-24 and
28-32 weeks of gestation and were therefore eligible for
two doses of IPTp.
In summary, this analysis shows that women attended
in accordance with the restrictive guidelines and ANC
attendance initiated later than 24 weeks of gestation was
low. Thus, the majority of women attended at the right
time to receive IPTp during the two IPTp delivery
periods.
Health workers’ IPTp delivery and its timing
ANC card records showed that delivery coverage was
high for one IPTp dose but low for the complete course
of two IPTp doses. Table 2 illustrates that among the
women who were 20 weeks of gestation and older, 21%
(79/370) had not yet received any IPTp dose and 79%
(291/370) were given one or more doses of IPTp.
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Table 2 IPTp delivery
Characteristic % (n/N)
Use of IPTp-SP
None 21.4 (79/370)*
At least one 78.7 (291/370)*
At least two 26.9 (46/171)**
Gestational age at 1st IPTp-SP dose
<20 week 4.7 (14/299)
20-24 weeks 72.9 (218/299)
>24 weeks 22.4 (67/299)
Gestational age at 2nd IPTp-SP dose
<28 weeks 11.8 (6/51)
28-32 weeks 84.3 (43/51)
>32 weeks 3.9 (2/51)
*No. of women of at least 20 weeks of gestation, **No. of women of at least
28 weeks of gestation.
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However, only 27% (46/171) of the women who were at
least 28 weeks of gestation had received two or more
doses.
Analysis of IPTp delivery by women’s gestational age
showed that the timing of the IPTp delivery was in
accordance with the restrictive IPTp guidelines (Table
2): most women received IPTp during the specific peri-
ods of 20-24 and 28-32 weeks of gestation. 73% (218/
299) of the women who had received a first dose of
IPTp got it between 20-24 weeks; 5% (14/299) received
it before and 22% (67/299) after this period. Among the
women who had received a second dose of IPTp, 84%
(43/51) got it between 28-32 weeks of gestation. Among
the total SP doses administered to pregnant women
only 11% (38/352) were distributed outside the two
delivery periods.
However, although most women attended the ANC
clinics during the required periods of 20-24 and/or 28-
32 weeks of gestation, several women did not receive
IPTp from the health workers, especially when attending
between 28-32 weeks of gestation. Using data from the
two subgroups, Table 3 reports the number of women
who attended ANC on time to be eligible for a dose of
IPTp and actually received IPTp. Among the women
who were at least 20 weeks of gestation, 81% (299/370)
attended between 20-24 weeks. Out of those, 73% (218/
299) received IPTp when they attended between 20-24
weeks. Among the women who were at least 28 weeks
of gestation, 92% (157/171) of the women attended the
ANC clinics at least once between 28-32 weeks. How-
ever, only 55% (87/157) of them got an IPTp dose either
as a first or a second dose. This suggests that health
workers deliver IPTp significantly less well between 28-
32 week of gestation than between 20-24 weeks (55.4%
vs. 72.9%; p < 0.001). Consequently, the coverage for
two doses of IPTp was low: among those who attended
during both IPT delivery periods (at 20-24 weeks and
28-32 weeks of gestation) only 30% (30/102) actually
received two doses of IPTp.
To summarize, analysis of health workers’ IPTp deliv-
ery showed that they adhered well to the restrictive
guidelines as far as timing of IPTp delivery is concerned.
However, women attending ANC clinics between 28-32
weeks of gestation were 24% (100%-55.4%/72.9%) less
likely to receive a dose of IPTp than women attending
between 20-24 weeks of gestation. Consequently, second
dose coverage was low.
IPTp guidelines compared
Opportunities to reach high IPTp coverage levels were
not only missed because of undelivered IPTp doses at
the health facilities, but also due to the poor implemen-
tation of the IPTp strategy. In fact, these two aspects
may be closely interlinked. Although WHO’s simplified
IPTp schedule from 2004 has been integrated into the
Tanzanian FANC guidelines the same year, health work-
ers at the ANC clinics still followed the former IPTp
policy and administered IPTp during two restrictive per-
iods in 2007 and 2008. Using the information on num-
ber and timing of ANC visits and received IPTp doses
among the study population, an estimate of the increase
in IPTp coverage that could potentially have been
gained by implementing the simplified WHO guidelines
was calculated. Table 4 summarizes the additional num-
ber of women from the survey sample who would have
been eligible to IPTp according to the simplified IPTp
guidelines recommended by the WHO compared to the
restrictive IPTp schedule currently practiced at the ANC
clinics. Women’s first visit was analysed to assess the
additional number of women eligible for one IPTp dose
and women’s first two, three and four visits were exam-
ined to assess the number of additional women eligible
for two doses of IPTp. Among the women who attended
the ANC clinic for the first time, a significantly higher
proportion of women would have been able to receive
one IPTp dose (69% vs. 57%, p < 0.001). At the first two
visits, IPTp coverage could have been increased by 19
percentage points (p < 0.001); and at the first three visits
by 20 percentage points (p < 0.001) by adhering to the
simplified guidelines. At the level of four ANC visits no
difference between the two guidelines was observable
due to the small sample size (N = 20).
Furthermore, according to the simplified guidelines
health workers would not only have been able to deliver
two IPTp doses at the right time to more women, but
could also have administered more than two IPTp doses
to 20% (37/189) of the women who attended the ANC
clinic at least twice.
Table 3 Women’s timing of ANC attendance and SP delivery
No. of women attending between 20-24 weeks
and/or 28-32 weeks of gestation at any visit
No. of women receiving SP between 20-24 weeks
and/or 28-32 weeks of gestation at any visit
% (CI 95%) n/N % (CI 95%) n/N
20-24 weeks of gestation 80.8 (76.4-84.7) 299/370* 72.9 (67.5-77.9) 218/299
28-32 weeks of gestation 91.8 (86.6-95.5) 157/171** 55.4 (47.3-63.3) 87/157
20-24 AND 28-32 weeks of gestation 59.7 (51.9-67.1) 102/171** 29.4 (14.7-49.4) 30/102
*No. of women of at least 20 weeks of gestation, **No. of women of at least 28 weeks of gestation.
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In summary, through the implementation of the sim-
plified guidelines recommended by WHO IPTp coverage
at their first, second and third ANC visits could have
been increased by 12 to 20 percentage points. Moreover,
the number of delivered doses of IPTp could be
increased.
Lost effectiveness of IPTp strategy
Women’s timing of ANC attendance, health workers’
IPTp delivery and policy issues all influence IPTp cover-
age levels. Based on the collected ANC record data,
Figure 4 illustrates the impact of these bottlenecks on
the effectiveness of the IPTp strategy for the two avail-
able IPTp guidelines (restrictive vs. simplified): Out of
189 women who made at least two ANC visits, 7%
started ANC attendance too late to receive the first
IPTp dose timely according to the restrictive guidelines.
According to the simplified guidelines all of them would
have received IPTp in time. 54% (102/189) of the
women who made two or more ANC visits, would have
been eligible for two IPTp doses according to the
restrictive guidelines while 75% (141/189) of them
attended timely according to the simplified guidelines
(p < 0.001). Given the current IPTp delivery practices
observed among health workers, 45% (85/189) of the
women were given at least one dose of IPTp and 16%
(31/189) were given two doses of IPTp at the correct
time according to the restrictive guidelines. Applying the
simplified guidelines, 61% (115/189) received at least
one dose and 22% (42/189) at least two doses of IPTp at
the right time. This indicates that effectiveness of the
IPTp strategy is lost especially through policy issues and
health worker practices.
Discussion
The study illustrated the combined effect of women’s
timing of ANC attendance, health worker’s IPTp deliv-
ery and different delivery schedules of national IPTp
guidelines on IPTp coverage. This is in line with find-
ings of previous studies from Tanzania showing that low
IPTp coverage levels can not be attributed solely to
women’s late enrolment to ANC [26,30]. Instead, health
worker’s IPTp delivery practices and unclear IPTp
guidelines led to lost effectiveness of the IPTp strategy.
Thus, solutions need to be found at individual, facility
and policy level if the government of Tanzania aims at
reaching at least 80% of pregnant women with two IPTp
doses [22].
Compared to the restricted IPTp guidelines, pregnant
women initiated ANC attendance late, but still in time
to receive a first IPTp dose. Pregnant women in Tanza-
nia are recommended to attend ANC clinics for the first
time at 16 weeks of gestation [23]. Most women started
ANC attendance in their second trimester around 20
weeks of gestation. This is consistent with the national
average among facility users [48] and with findings from
other studies [26,28,30,31,35]. However, contrary to
health workers’ perception and assumptions in the lit-
erature [29,33,49,50], women’s late ANC enrolment did
not interfere with the IPTp schedule. This has also been
stressed by other studies [26,30,31]. Only 15% of the
Table 4 Number of women eligible for IPTp according to the two guidelines
Restrictive guidelines
(20-24, 28-32 weeks of gestation)
Simplified guidelines
(20-40 weeks of gestation, one month apart)
% (95% CI) n/N % (95% CI) n/N p-value*
Visits No. of women eligible
for one dose of IPTp
First visit 57.4
(52.6-62.2)
247/430 69.5
(64.9-73.8)
299/430 <0.001
No. of women eligible for at
least two doses of IPTp
First two visits 40.2 (33.2-47.6) 76/189 59.3 (51.9-66.3) 112/189 <0.001
First three visits 70.8 (58.9-80.9) 51/72 90.3 (81-96) 65/72 <0.001
First four visits 90.0 (68.3-98.7) 18/20 95.0 (75.1-99.9) 19/20 1.0
* P-values based on chi-square test and Fishers exact test at four visits.
Legend: Effectiveness indicators
1) At least 2 ANC visits
2) ANC attendance initiated in time for IPTp
3) ANC visits timed for 2 IPTp doses
4) ANC visits timed for 2 IPTp doses and received 1 IPTp dose
5) ANC visits timed for 2 IPTp doses and received at least 2 IPTp doses
Women’s 
delay
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Figure 4 Effectiveness loss of the IPTp strategy due to
individual, facility and policy factors
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women started ANC attendance after 24 weeks of gesta-
tion and were therefore according to the restrictive
guidelines no longer eligible for a first dose of IPTp.
Overall, women’s timing of ANC visits matched well
with the restrictive IPTp schedule that was practiced in
health facilities. The majority of the participants
attended the ANC clinic at least once between 20-24
weeks and between 28-32 weeks of gestation. This
shows that women’s ANC attendance follows health
workers’ instructions and was not the main cause for
low IPTp levels. IPTp coverage could theoretically have
been high. The high proportion of women attending
during the specific periods is not surprising as women
are given return dates by the health workers. Although
women’s knowledge about the timing of IPTp was not
investigated, it can be presumed that women rely on
health workers to correctly administer drugs [18,49].
Findings of Marchant et al. [30] support this assump-
tion: over 90% of the women who had not received a
dose of IPTp said that health workers had not offered it
to them. The participants’ knowledge on malaria pre-
vention and its effects was not very high. Almost a quar-
ter of the women did not know why they were supposed
to get malaria prevention at the ANC clinic. Pregnant
women’s knowledge concerning IPTp but also women’s
power and ability to actively demand IPTp and to pro-
tect themselves from erratic timing or missed delivery of
IPTp [36] needs to be improved.
Health workers’ IPTp delivery was characterized by its
focus on the restrictive IPTp guidelines and by low
delivery levels between 28-32 weeks of gestation. Timing
of IPTp delivery was in accordance with the restrictive
IPTp schedule as most IPTp doses were delivered within
the specified periods of 20-24 weeks and 28-32 weeks of
gestation. Only 11% of the total IPTp doses were admi-
nistered outside these periods. Awareness of the IPTp
strategy was high among the health workers, however,
the concurrent existence of different IPTp guidelines led
to some confusion about when and how many IPTp
doses to administer.
Consistent with findings from several other studies
[26,27,29,31,48], most women in the study got a first
dose of IPTp, but many did not receive a complete
course of two IPTp doses. HMIS data collected in the
study area in 2008 provided a similar picture: less than
half of the women who were given a first IPTp dose,
also received a second one. Health workers’ low perfor-
mance provides one possible explanation [50,51]: Obser-
vations of ANC consultations in the context of a study
on quality of care showed that return visits were usually
of very short duration and reduced to the most basic
examinations such as abdominal palpation and the mea-
surement of blood pressure and weight (Gross et al.,
submitted to BMC Pregnancy and Childbirth). In this
context, IPTp as well as the delivery of other drugs and
lab examinations might easily be skipped or forgotten.
This pattern has also been reported in a study from
Malawi [33]. Given the shortages of SP often observed
in Tanzania [26,30,52] health workers’ rationing of SP,
especially of the second IPTp dose, might represent
another possible explanation. Information on SP stock-
outs was not collected at the time of the study as it
would only have served to explain the missed delivery of
the most recent IPTp doses. Monitoring SP stocks at
the health facilities through the collection of end of
month drug stock data was not possible due to low
quality of record keeping by the facility staff. However, a
quality of care study conducted in October 2008 in the
same area showed that all the selected health facility
except one had SP available in the three preceding
months (unpublished data, ACCESS Programme). As
this study leaves open questions on why health workers
delivered the second IPTp dose significantly less well
than the first one, it calls for future studies on health
workers IPTp delivery practices.
IPTp delivery practices at ANC clinics in the study
area and other regions of Tanzania differ critically from
the simplified WHO recommendations to distribute SP
to all pregnant women twice after quickening and one
month apart [26,30]. The government’s failure to imple-
ment the simplified IPTp schedule caused on the one
hand confusion among health workers due to the con-
current existence of different and contradictory IPTp
policies. On the other hand it represents a missed
opportunity for high coverage levels of this important
intervention. Calculations based on the simplified guide-
lines suggest that IPTp coverage could potentially be
increased by up to 20 percentage points if IPTp delivery
were no longer limited to the narrow gestational range
of 20-24 and 28-32 weeks. Better outcomes are also to
be expected as health workers’ difficulties to assess
gestational age is taken into account [19].
The Ministry of Health should therefore overcome
inconsistent IPTp messages and advocate one clear
IPTp recommendation. The study showed that imple-
menting the simplified IPTp policy recommended by
WHO has the potential to reach more pregnant women
with the important intervention of IPTp. The fact that
the simplified IPTp guidelines are already integrated in
the Focused Antenatal Care guidelines highlights the
need for training health workers on the new policy and
disseminating the information to the periphery.
Not only coverage but also the number of adminis-
tered doses could be easily increased through the imple-
mentation of the simplified guidelines. WHO currently
recommends a three dose regimen for areas in which
antenatal HIV prevalence exceeds 10% and where HIV-
testing is not available [53]. Trials from Kenya, Malawi
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and Zambia showed that receiving at least three courses
of IPTp was associated with a better protective outcome
among HIV-positive pregnant women [15,54-56]. Tanza-
nia so far continues with a two-dose regimen due to its
relatively low HIV prevalence rates. However, if levels of
parasite resistance continue to increase, alternative
drugs for IPTp need to be urgently found [57]. Any
replacement drug to SP will most likely require a more
complicated drug regimen. Thus, achieving high cover-
age levels will become even more challenging.
Collecting data through exit interviews at health facil-
ities imposed two main limitations on the study: Firstly,
information on women’s ANC attendance behaviour
was incomplete. Most women were at the beginning or
at the middle of their pregnancy and data were usually
available for less than four ANC visits. Moreover,
although data collection took place over several months
and at different ANC clinics it might not be representa-
tive for other places and periods of the year. Secondly,
the conduct of exit interviews may have resulted in
improved health worker performance. Including ANC
card data on services received at earlier visits certainly
lessened this type of bias. In reality, having a record of
IPTp receipt is neither a guarantee that the drug was
given nor taken - despite the fact that IPTp should be
provided under direct observation. However, comparing
ANC records with women’s self-report revealed no
major inconsistencies.
Finally, between the interviews with the health work-
ers and the exit interviews with ANC attendees was a
time gap of one year, since the exit interview survey was
conducted in order to verify and validate certain results
from the health worker interviews. Although health
workers did not receive any training on IPTp delivery in
the meantime, the time order of the studies did not
allow to investigate health workers’ reasons for the
lower level of second dose IPTp delivery.
Conclusions
This study showed that effective IPTp delivery to preg-
nant women is hampered by the combined effect of
women’s timing of ANC attendance, health worker’s
IPTp delivery and different delivery schedules of
national IPTp guidelines. In particular, the implementa-
tion of simplified IPTp guidelines will be critical for
reaching the 80% target. Training on simplified IPTp
messages should be reinforced as part of the extended
FANC training of health workers to change IPTp deliv-
ery practices and increase coverage levels. Additionally,
campaigns that provide educational messages on the
risk of malaria during pregnancy and the usefulness of
IPTp and that help to raise patients’ awareness for their
rights are required to increase pregnant women’s power
to demand IPTp and other ANC services and decrease
their dependence on health workers. Lessons need to be
learned on how to implement guidelines changes effec-
tively and determinedly in order to be prepared for the
implementation of a new drug for IPTp when drug
resistance against SP has reached levels where IPTp
with SP is no longer efficacious.
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